Literature DB >> 15099954

Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.

Andreas Widschwendter1, Hannes M Müller, Michael M Hubalek, Annemarie Wiedemair, Heidi Fiegl, Georg Goebel, Elisabeth Mueller-Holzner, Christian Marth, Martin Widschwendter.   

Abstract

OBJECTIVES: Activation of telomerase, the enzyme that synthesizes the telomere ends of linear chromosomes, has been implicated in human cell immortalization and cancer cell pathogenesis. The expression pattern of human telomerase reverse transcriptase (hTERT), the telomerase catalytic subunit gene, is correlated with telomerase activity. The promotor region of the hTERT gene has been located in a CpG island and may therefore be regulated, at least in part, by DNA methylation. The potential for methylation-mediated regulation of hTERT gene expression in ovarian and cervical cancer tissue has not been investigated up to now. The aim of this study was to investigate the expression and methylation pattern of hTERT in ovarian and cervical cancer tissue and their correlation with clinicopathological features and outcome of the disease.
METHODS: A total of 223 tissues were analyzed for hTERT methylation using MethyLight: 65 patients with cervical cancer and 124 with ovarian cancer were studied. The control group consisted of 20 normal ovarian tissues and 14 normal cervical tissues. Quantitative hTERT expression analysis was carried out in a subgroup of patients using real time PCR.
RESULTS: hTERT expression was statistically significantly higher in ovarian and cervical cancer tissue in comparison to normal tissue. While methylation of hTERT in cervical cancer was significantly more frequent in comparison to normal cervical tissue, the difference between ovarian cancer and normal ovarian tissue was not significant. No correlation was detected between hypermethylation of hTERT and hTERT mRNA expression. Both ovarian cancer and normal ovary showed an increase in hTERT methylation with increasing age. hTERT expression was not correlated with prognosis, whereas cervical and ovarian cancer patients with unmethylated hTERT had significantly better overall survival.
CONCLUSION: At least in some tumor entities, hTERT methylation is a function of age and is associated with a poorer outcome, irrespective of hTERT expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099954     DOI: 10.1016/j.ygyno.2004.01.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

Review 1.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

2.  Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis.

Authors:  Seungjae Lee; Sumit Borah; Armita Bahrami
Journal:  J Mol Diagn       Date:  2017-03-09       Impact factor: 5.568

Review 3.  Epigenomics and ovarian carcinoma.

Authors:  Leonel Maldonado; Mohammad Obaidul Hoque
Journal:  Biomark Med       Date:  2010-08       Impact factor: 2.851

4.  High-throughput DNA methylation profiling using universal bead arrays.

Authors:  Marina Bibikova; Zhenwu Lin; Lixin Zhou; Eugene Chudin; Eliza Wickham Garcia; Bonnie Wu; Dennis Doucet; Neal J Thomas; Yunhua Wang; Ekkehard Vollmer; Torsten Goldmann; Carola Seifart; Wei Jiang; David L Barker; Mark S Chee; Joanna Floros; Jian-Bing Fan
Journal:  Genome Res       Date:  2006-01-31       Impact factor: 9.043

Review 5.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

6.  hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis.

Authors:  Jillian de Wilde; Jan M Kooter; Renée M Overmeer; Debbie Claassen-Kramer; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

7.  Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.

Authors:  Hsien-Neng Huang; Ying-Cheng Chiang; Wen-Fang Cheng; Chi-An Chen; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

8.  hTERT Protein Expression in Cytoplasm and Nucleus and its Association With HPV Infection in Patients With Cervical Cancer.

Authors:  Pablo Moreno-Acosta; MÓnica Molano; Nicolas Morales; Jinneth Acosta; Cristian GonzÁlez-Prieto; Diana Mayorga; Lina Buitrago; Oscar Gamboa; Juan Carlos MejÍa; July Castro; Alfredo Romero-Rojas; Sophie Espenel; Gerald L Murray; Suzanne M Garland; Alexis Vallard; Nicolas MagnÉ
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

9.  PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells.

Authors:  Stéphanie Bougel; Stéphanie Renaud; Richard Braunschweig; Dmitri Loukinov; Herbert C Morse; Fred T Bosman; Victor Lobanenkov; Jean Benhattar
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

10.  Expression of phosphorylated Akt and hTERT is associated with prognosis of epithelial ovarian carcinoma.

Authors:  Yoo-Kyung Lee; Hyun Hoon Chung; Jae Weon Kim; Yong-Sang Song; Noh-Hyun Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.